A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy (SBRT) Prior to Radical Prostatectomy (RP) in Locally Advanced Prostate Cancer

CONCLUSION: Neoadjuvant SBRT to 30-35 Gy in 5 fractions followed by RP results in unacceptably high toxicity and severe QoL declines. Locoregional only treatment intensification is oncologically inadequate, as nearly half of men having recurred by 3 years post-treatment. Given the success of definitive radiotherapy plus hormone therapy in locally advanced prostate cancer, the combination of neoadjuvant SBRT and RP should not be further pursued.PMID:34700572 | DOI:10.1016/j.ijrobp.2021.07.134

Source: Ann Oncol - October 27, 2021 Category: Cancer & Oncology Authors: L Hammer R Jiang J W D Hearn R T Dess W C Jackson Z Reichert S Kaffenberger A George J Montgomery S Salami T M Morgan D C Miller B Hollenbeck D Wittman R Mehra M Davenport S Daignault-Newton M Schipper G Palapattu D E Spratt Source Type: research